Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016.. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MlzsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFX1UXFKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKDNwNk\lMVA2KM7:TR?= Mk\SV2FPT0WU
CAL-51 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3SxeWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2= MkHXV2FPT0WU
ABC-1 cell M{fvUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlUhdk1? MUTTRW5ITVJ?
A2780 cell MnHDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\XNmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6PCCwTR?= NUDK[4g6W0GQR1XS
ES1 cell NH7wPHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;pTYhpUW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc1QSCwTR?= M3voXXNCVkeHUh?=
HUTU-80 cell NF7yT3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\zWWlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzlzIH7N MV\TRW5ITVJ?
NCI-H292 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIDUWllKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0> Ml3IV2FPT0WU
NB69 cell NXm1Tmk2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MULJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkKyJI5O M{HrV3NCVkeHUh?=
ES8 cell M1r4bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmHmTY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkOyJI5O MVnTRW5ITVJ?
BCPAP cell MmHsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV[2Xm1UUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= M2X3U3NCVkeHUh?=
T-24 cell MkXRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnrnTY5pcWKrdHnvckBw\iCqdX3hckBVNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61OUBvVQ>? MULTRW5ITVJ?
EW-16 cell NF24XG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? NETTOJdUSU6JRWK=
OVCAR-5 cell MkHuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{KG6P NIHDdIZUSU6JRWK=
SF126 cell M1rIO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlTHTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUhdk1? MXvTRW5ITVJ?
KP-4 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGtRNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkG3JI5O NEP0S4NUSU6JRWK=
GAMG cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlXhTY5pcWKrdHnvckBw\iCqdX3hckBISU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NUBvVQ>? NGrOWo1USU6JRWK=
HOS cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4f2TGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61N{BvVQ>? NFjtOGFUSU6JRWK=
CHL-1 cell NWjOc4J{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGi2dWdKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?= M3zM[3NCVkeHUh?=
AGS cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M37WWGlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj64OkBvVQ>? NGW4O|dUSU6JRWK=
MDA-MB-157 cell MoS3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HDS2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUKgcm0> MmDDV2FPT0WU
HSC-3 cell MljxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlH3TY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? NXnqUGZ7W0GQR1XS
CAL-72 cell NVLpOpg1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC15MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? Mm\3V2FPT0WU
NBsusSR cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUDJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE{KG6P MWTTRW5ITVJ?
ES7 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjqcodKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVkhdk1? MlPFV2FPT0WU
H-EMC-SS cell M2\ufmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?= NF3We3JUSU6JRWK=
NCI-H1703 cell MoXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mnq4TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N MVTTRW5ITVJ?
BHT-101 cell NXHnO3k{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4HDSGlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzJibl2= MkTkV2FPT0WU
SK-OV-3 cell MoezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfNbHVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd3IH7N MYHTRW5ITVJ?
EW-24 cell MorwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64N{BvVQ>? MXjTRW5ITVJ?
PSN1 cell NFfydpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGfhRplKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg1KG6P MV\TRW5ITVJ?
OVCAR-8 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\DN|BKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njl7IH7N M4Hqc3NCVkeHUh?=
NCI-H1563 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3nmNWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> NX;0fIZwW0GQR1XS
SW756 cell M3rU[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? NEjBfG1USU6JRWK=
A375 cell MlW0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG0JI5O NED4ToVUSU6JRWK=
Ca9-22 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4nT[mlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zPSCwTR?= M2rRUXNCVkeHUh?=
SW1990 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\YTY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P NEHSNHNUSU6JRWK=
ES4 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjRTY5pcWKrdHnvckBw\iCqdX3hckBGWzRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkO5JI5O NH7iPVNUSU6JRWK=
HCE-T cell NXeyZYJwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3;LZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ2KG6P M{DxcHNCVkeHUh?=
MOLT-16 cell MmHMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlU{KG6P NXnHUGtwW0GQR1XS
HSC-4 cell NGjJXoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnXrTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPEBvVQ>? NFzTU3FUSU6JRWK=
NCI-SNU-1 cell MlPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mni1TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njh4IH7N NVP1[mpqW0GQR1XS
EW-11 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH\IcZhKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P MWDTRW5ITVJ?
HT-1080 cell NV3we5NQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1rRNWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlibl2= NXe2fG5JW0GQR1XS
MES-SA/Dx5 cells MYnDfZRwfG:6aXPpeJkh[XO|YYm= NIn4dXFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0> MoDCNlM6Ozd7OEG=
SW1710 cell M3zXZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYjJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNVYhdk1? NWLiWIJsW0GQR1XS
EW-1 cell MljoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkK0JI5O NFXBbItUSU6JRWK=
BV-173 cell M4LD[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3XHZ2lvcGmkaYTpc44hd2ZiaIXtZY4hSlZvMUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{QSCwTR?= Ml;0V2FPT0WU
TE-8 cell M1nINGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLZTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60NUBvVQ>? MUPTRW5ITVJ?
G-401 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4fIR2lvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ{KG6P MoS2V2FPT0WU
KOSC-2 cell MnTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlvjTY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ2KG6P M4iwNXNCVkeHUh?=
HuCCT1 cell NGjseZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVIhdk1? NUf4cWJ7W0GQR1XS
FADU cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVH5SZlEUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43PiCwTR?= MmXFV2FPT0WU
MHH-ES-1 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;6TY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjlibl2= M2LDXnNCVkeHUh?=
ES3 cell NUPoUHlMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWTyVGtFUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6KG6P MWPTRW5ITVJ?
OVCAR-4 cell M{L4[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlPFTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU45PyCwTR?= M4fCOnNCVkeHUh?=
HD-MY-Z cell NYrab3JYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P NG[5c2xUSU6JRWK=
human JAR cell M1;DUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWi3eIhtUW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk4KG6P NXTHR5pLW0GQR1XS
A427 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrGTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6wO{BvVQ>? NIPhVWJUSU6JRWK=
697 cell NX;pPWh4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWjLSFluUW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE{KG6P M17UNHNCVkeHUh?=
OVCAR-3 cell NGHlW2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MljFTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zKG6P NXO5SHFFW0GQR1XS
human NB14 cell M2DTXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHkTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj62OEBvVQ>? NYfEPHc6W0GQR1XS
GB-1 cell NEDnXGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWH6c3RbUW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?= M3[yPXNCVkeHUh?=
COR-L105 cell M2PK[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXaOZBKUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwN{[gcm0> M37hVHNCVkeHUh?=
647-V cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{\LbWlvcGmkaYTpc44hd2ZiaIXtZY4hPjR5LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlkhdk1? NVjIZYU4W0GQR1XS
human K5 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn3uTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdibl2= NYmzXmFqW0GQR1XS
DMS-273 cell NHLJVWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHQTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= MkWyV2FPT0WU
UM-UC-3 cell M2riNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYL4fWpbUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> NH\SWlJUSU6JRWK=
HEL cell NH30UGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUfke|AxUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA5KG6P NGDtbVFUSU6JRWK=
human KU-19-19 cell NWrIbpo2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHXxN3BKdmirYnn0bY9vKG:oIHj1cYFvKEuXLUG5MVE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yOTDuUS=> Ml7JV2FPT0WU
MC-IXC cell M3zVbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M33tU2lvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?= NGTxWGhUSU6JRWK=
human H4 cell NI\2dnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrwTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMkWgcm0> NUfHSmNtW0GQR1XS
NUGC-3 cell M1jJPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnTITY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P NFi5W29USU6JRWK=
CHP-212 cell M3r4RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYPxepZVUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|NDDuUS=> NWDCdIRWW0GQR1XS
human SW982 cell NYLXPHlmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mlv0TY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOFQhdk1? NVfXe4VYW0GQR1XS
C-33-A cell MkPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXv0OW5nUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N Ml3hV2FPT0WU
PC-3 cell MoD1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki5JI5O M1H3V3NCVkeHUh?=
COLO-684 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX3YXXFkUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTlwMkGgcm0> M1m3[nNCVkeHUh?=
SNU-387 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4OxdGlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPDlibl2= NEDGfmRUSU6JRWK=
U251 cell M4jFXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXTXXlFtUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU45PiCwTR?= Mne1V2FPT0WU
A673 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXHvdJNbUW6qaXLpeIlwdiCxZjDoeY1idiCDNkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPiCwTR?= NVW3Z4NMW0GQR1XS
human T47D cell M{TGeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MljPTY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MU[uO|khdk1? MlfCV2FPT0WU
A549 cell NEeyVplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHrCOJRKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU43KG6P MorsV2FPT0WU
PC-14 cell M1nIeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M32wWmlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE44OyCwTR?= NXG3TohLW0GQR1XS
A704 cell NUfZemFoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoXsTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkeuOFUhdk1? M1PmO3NCVkeHUh?=
MCF7 cell NHzjfXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPWbYxKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?= NIHSOndUSU6JRWK=
PC3 cells M1zwc2Z2dmO2aX;uJIF{e2G7 NGXDemRKdmirYnn0bY9vKG:oIGDET|EudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhicnXzbYR2\SCrbjDoeY1idiCSQ{OgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC5zMUOg{txO MUGyNVM1OTZ5NR?=
F-36P cells M4HS[HBzd2yrZnXyZZRqd25iYYPzZZk> MofoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>? NXjQO3BIOjF|NEG2O|U>
OCI-AML2 cells NEm0c3FRem:uaX\ldoF1cW:wIHHzd4F6 MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN|Uh|ryP MXuyNVM1OTZ5NR?=
K562 cells NHS0PHpRem:uaX\ldoF1cW:wIHHzd4F6 NVjwbWZnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? NYTjVGhFOjF|NEG2O|U>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Unknown status Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID